Our data strongly suggest that the induction of ZNF224 expression could provide promising means to circumvent imatinib resistance and to develop new therapeutic approaches in CML. The gene discussed is ZNF224; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.